June Lee - Net Worth and Insider Trading

June Lee Net Worth

The estimated net worth of June Lee is at least $934,051 dollars as of 2024-04-27. June Lee is the EVP, Chief Development Officer of MyoKardia Inc and owns about 4,153 shares of MyoKardia Inc (MYOK) stock worth over $934,051. Details can be seen in June Lee's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that June Lee has not made any transactions after 2019-09-23 and currently still holds the listed stock(s).

Transaction Summary of June Lee

June Lee Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, June Lee owns 4 companies in total, including MyoKardia Inc (MYOK) , Eledon Pharmaceuticals Inc (ELDN) , and Tenaya Therapeutics Inc (TNYA) among others .

Click here to see the complete history of June Lee’s form 4 insider trades.

Insider Ownership Summary of June Lee

Ticker	Comapny	Transaction Date	Type of Owner
MYOK	MyoKardia Inc	2019-09-23	EVP & Chief Development Officer
ELDN	Eledon Pharmaceuticals Inc	2020-12-08	director
TNYA	Tenaya Therapeutics Inc	2021-11-19	director
CINC	CinCor Pharma Inc	2022-01-06	director

June Lee Latest Holdings Summary

June Lee currently owns a total of 1 stock. June Lee owns 4,153 shares of MyoKardia Inc (MYOK) as of September 23, 2019, with a value of $934,051.

Latest Holdings of June Lee

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MYOK	MyoKardia Inc	2019-09-23	4,153	224.91	934,051

Holding Weightings of June Lee

June Lee Form 4 Trading Tracker

According to the SEC Form 4 filings, June Lee has made a total of 3 transactions in MyoKardia Inc (MYOK) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in MyoKardia Inc is the sale of 13,051 shares on September 23, 2019, which brought June Lee around $776,665.

Insider Trading History of June Lee

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

June Lee Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

June Lee Ownership Network

Ownership Network List of June Lee

No Data

Ownership Network Relation of June Lee

June Lee Owned Company Details

What does MyoKardia Inc do?

Who are the key executives at MyoKardia Inc?

June Lee is the EVP & Chief Development Officer of MyoKardia Inc. Other key executives at MyoKardia Inc include director & President and CEO Anastasios Gianakakos , General Counsel Denelle J Waynick , and Chief Business Officer Jake Bauer .

MyoKardia Inc (MYOK) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of MyoKardia Inc (MYOK) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MyoKardia Inc (MYOK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

MyoKardia Inc (MYOK)'s detailed insider trading history can be found in Insider Trading Tracker table.

MyoKardia Inc Insider Transactions

No Available Data

What does Eledon Pharmaceuticals Inc do?

Who are the key executives at Eledon Pharmaceuticals Inc?

June Lee is the director of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .

Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary

Over the past 18 months, June Lee made no insider transaction in Eledon Pharmaceuticals Inc (ELDN). Other recent insider transactions involving Eledon Pharmaceuticals Inc (ELDN) include a net purchase of 1,978,932 shares made by Biotechnology Value Fund L P , and a net purchase of 1,000 shares made by Steven Perrin .

In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 1,979,932 shares were bought by its insiders, resulting in a net purchase of 1,979,932 shares.

Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eledon Pharmaceuticals Inc Insider Transactions

No Available Data

What does Tenaya Therapeutics Inc do?

Who are the key executives at Tenaya Therapeutics Inc?

June Lee is the director of Tenaya Therapeutics Inc. Other key executives at Tenaya Therapeutics Inc include Chief Scientific Officer Timothy Hoey , Chief Fin and Bus. Officer Leone D Patterson , and director & Chief Executive Officer Faraz Ali .

Tenaya Therapeutics Inc (TNYA) Insider Trades Summary

Over the past 18 months, June Lee made no insider transaction in Tenaya Therapeutics Inc (TNYA). Other recent insider transactions involving Tenaya Therapeutics Inc (TNYA) include a net purchase of 13,599,275 shares made by Column Group Iii Gp, Lp , a net purchase of 13,599,275 shares made by David V Goeddel , and a net sale of 25,800 shares made by Timothy Hoey .

In summary, during the past 3 months, insiders sold 32,609 shares of Tenaya Therapeutics Inc (TNYA) in total and bought 4,444,444 shares, with a net purchase of 4,411,835 shares. During the past 18 months, 59,437 shares of Tenaya Therapeutics Inc (TNYA) were sold and 29,921,361 shares were bought by its insiders, resulting in a net purchase of 29,861,924 shares.

Tenaya Therapeutics Inc (TNYA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tenaya Therapeutics Inc Insider Transactions

No Available Data

What does CinCor Pharma Inc do?

Who are the key executives at CinCor Pharma Inc?

June Lee is the director of CinCor Pharma Inc. Other key executives at CinCor Pharma Inc include director & 10 percent owner James Healy , 10 percent owner Sofinnova Management X-a, L.l.c. , and EVP & Chief Financial Officer Michael Wayne Kalb .

CinCor Pharma Inc (CINC) Insider Trades Summary

Over the past 18 months, June Lee made no insider transaction in CinCor Pharma Inc (CINC). Other recent insider transactions involving CinCor Pharma Inc (CINC) include a net sale of 6,000 shares made by James Healy ,

In summary, during the past 3 months, insiders sold 0 shares of CinCor Pharma Inc (CINC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000 shares of CinCor Pharma Inc (CINC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000 shares.

CinCor Pharma Inc (CINC)'s detailed insider trading history can be found in Insider Trading Tracker table.

CinCor Pharma Inc Insider Transactions

No Available Data

June Lee Mailing Address

Above is the net worth, insider trading, and ownership report for June Lee. You might contact June Lee via mailing address: C/o Myokardia, Inc., 333 Allerton Ave, South San Francisco Ca 94080.

Discussions on June Lee

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.